CARE NEEDS AND HEALTHCARE RESOURCE UTILIZATION AMONG 5-2-1-POSITIVE VS 5-2-1-NEGATIVE PEOPLE WITH PARKINSON'S DISEASE IN AN INTERNATIONAL REAL-WORLD DATASET
Author(s)
Daniel Gratie, PharmD, MS1, Reethi Iyengar, PhD, MBA1, Inyoung Lee, PhD2, Jae Hyun Lee, MS, PharmD2, Jaclyn Homola, PharmD1, Lars Bergmann, MD1, Abdallah Saad, MPH, BPharm1, Daniel Mascia, BSc3, Alexander Gillespie, BSc3.
1AbbVie Inc., North Chicago, IL, USA, 2AbbVie, North Chicago, IL, USA, 3ADELPHI REAL WORLD, Adelphi Mill, United Kingdom.
1AbbVie Inc., North Chicago, IL, USA, 2AbbVie, North Chicago, IL, USA, 3ADELPHI REAL WORLD, Adelphi Mill, United Kingdom.
OBJECTIVES: To evaluate the burden associated with 5-2-1 status in people with Parkinson’s disease (PwP).
METHODS: Interim data from the UK, Germany, Italy, France, Spain, and Japan were analyzed from the Adelphi Real World Parkinson’s Disease Wave X Disease Specific Programme, a retrospective, cross-sectional survey carried out November 2025—June 2026. This is an update to the 2017—2020 Wave VII/VIII survey. Physicians reported on their patients treated for Parkinson’s disease (PD). Patients on oral therapy and not receiving subcutaneous infusions or device-aided therapy were eligible for this analysis. Patients who were 5-2-1-positive were considered to be suboptimally controlled on oral therapy. Physician-reported outcomes included patient characteristics, symptom burden, and healthcare resource utilization (HCRU). T-tests and chi-square tests assessed differences between 5-2-1-positive-PwP vs 5-2-1-negative-PwP.
RESULTS: 5-2-1-positive-PwP (n=712) were older (mean 72.3 vs 70.2 years, P<.05) and had a longer time since PD diagnosis (mean 5.5 vs 3.3 years, P<.05) than 5-2-1-negative-PwP (n=255). 5-2-1-positive-PwP also had more mean daily Off time (3.2 vs 0.2 hours), On time with dyskinesia (3.0 vs 0.0 hours), and Off time when trying to sleep (1.5 vs 0.2 hours, all P-values <.05). 5-2-1-positive-PwP required additional support from a caregiver or healthcare professional (73% vs 38%) due to their health problems, including partners or spouses spending double the care hours per week (30.8 [n=188] vs 14.6 [n=35], P<.05). 5-2-1-positive-PwP had more neurologist visits (1.8 [n=303] vs 1.3 [n=51]), were more likely to report a fall due to PD (25% vs 8%), and had more mean PD-related hospitalizations (0.2 [n=645] vs 0.1 [n=235]) in the last year (all P-values <.05).
CONCLUSIONS: This study highlights persistent unmet need among patients uncontrolled on oral therapy, including many 5-2-1-positive patients diagnosed within the last 5 years. Despite recent advances in treatments, these findings underscore the need to escalate treatment to improve care in PD.
METHODS: Interim data from the UK, Germany, Italy, France, Spain, and Japan were analyzed from the Adelphi Real World Parkinson’s Disease Wave X Disease Specific Programme, a retrospective, cross-sectional survey carried out November 2025—June 2026. This is an update to the 2017—2020 Wave VII/VIII survey. Physicians reported on their patients treated for Parkinson’s disease (PD). Patients on oral therapy and not receiving subcutaneous infusions or device-aided therapy were eligible for this analysis. Patients who were 5-2-1-positive were considered to be suboptimally controlled on oral therapy. Physician-reported outcomes included patient characteristics, symptom burden, and healthcare resource utilization (HCRU). T-tests and chi-square tests assessed differences between 5-2-1-positive-PwP vs 5-2-1-negative-PwP.
RESULTS: 5-2-1-positive-PwP (n=712) were older (mean 72.3 vs 70.2 years, P<.05) and had a longer time since PD diagnosis (mean 5.5 vs 3.3 years, P<.05) than 5-2-1-negative-PwP (n=255). 5-2-1-positive-PwP also had more mean daily Off time (3.2 vs 0.2 hours), On time with dyskinesia (3.0 vs 0.0 hours), and Off time when trying to sleep (1.5 vs 0.2 hours, all P-values <.05). 5-2-1-positive-PwP required additional support from a caregiver or healthcare professional (73% vs 38%) due to their health problems, including partners or spouses spending double the care hours per week (30.8 [n=188] vs 14.6 [n=35], P<.05). 5-2-1-positive-PwP had more neurologist visits (1.8 [n=303] vs 1.3 [n=51]), were more likely to report a fall due to PD (25% vs 8%), and had more mean PD-related hospitalizations (0.2 [n=645] vs 0.1 [n=235]) in the last year (all P-values <.05).
CONCLUSIONS: This study highlights persistent unmet need among patients uncontrolled on oral therapy, including many 5-2-1-positive patients diagnosed within the last 5 years. Despite recent advances in treatments, these findings underscore the need to escalate treatment to improve care in PD.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
EPH77
Topic
Epidemiology & Public Health
Topic Subcategory
Public Health
Disease
Neurological Disorders